{"id":"W3024082028","doi":"10.1007/s10637-020-00928-z","title":"A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Cetuximab; Medicine; KRAS; Colorectal cancer; Pharmacodynamics; Internal medicine; Adverse effect; Oncology; Pharmacokinetics; Response Evaluation Criteria in Solid Tumors; EGFR inhibitors; Epidermal growth factor receptor; Toxicity; Phases of clinical research; Cancer; Monoclonal antibody; Pharmacology; Antibody; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001533118,0.001474661,0.002887746,0.000522593,0.0006050867,0.001213219,0.0008388294,0.001762023,0.003992265],"category_scores_gemma":[0.001274384,0.0008621907,0.002269191,0.0005226745,0.0008277635,0.001100537,0.0003807102,0.004407876,0.0007556493],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001323999,"about_ca_system_score_gemma":0.001815683,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002499434,"about_ca_topic_score_gemma":0.007892653,"domain_scores_codex":[0.9995149,0.0002157056,0.00002187383,0.00008536503,0.00003899725,0.0001231658],"domain_scores_gemma":[0.9992231,0.0001377165,0.00009408618,0.00005077031,0.00005970788,0.0004346056],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8793407,0.04956114,0.004952309,0.0006977787,0.001911129,0.0002355103,0.0002007065,0.001817144,0.01500047,0.0001864298,0.002900821,0.04319585],"study_design_scores_gemma":[0.6699393,0.3120328,0.0125835,0.00003069206,0.0007083857,0.0001744742,0.00006564315,0.0009995687,0.001384413,0.00009460494,0.001953511,0.00003311598],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928238,0.002223802,0.0002384055,0.0006269958,0.0002481914,0.001350592,0.000811844,0.00004467894,0.001631631],"genre_scores_gemma":[0.9906529,0.001955322,0.0008733759,0.0009171678,0.0002303352,0.001180556,0.001848574,0.00002242126,0.002319421],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003992265,"threshold_uncertainty_score":0.01335543,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01769703272519022,"score_gpt":0.2963037684540168,"score_spread":0.2786067357288266,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}